Pancreatogenic Diabetes Or Type 3c Diabetes (T3cD) Is Being Misdiagnosed As Type 2 Diabetes (T2D)
The researchers have identified the new type 3c diabetes (also known as pancreatogenic diabetes, a subtype of type 3 diabetes. T3cD). The damage to the pancreas due to the tumors, inflammation or surgery may trigger the development of type 3c diabetes. Type 3c diabetes can reduce the insulin secretion from beta cells (required to control blood glucose levels. Glycemic control) and also reduce the secretion of digestive enzymes (proteins) and other hormones (for the digestion of the food).
Pancreatogenic diabetes (T3cD) may not be developed in all people from pancreas diseases, damage or injury. Diabetes development may take more than ten years in most of the people from pancreatic disease, damage or injury.
But, type 3c diabetes is being misdiagnosed as type 2 diabetes by their doctors due to the delay in the development of type 3c diabetes. The medical professionals were failed to find an association between the pancreas diseases (damage or injury) and pancreatogenic diabetes (or the development of type 3c diabetes. T3cD).
A large-scale study was conducted on two million patients, all age groups, in England. The researchers have used the Royal College of General Practitioners Research and Surveillance Database (RCGP RSC) to find out the prevalence of type 3c diabetes. The study also focused on finding how patients of type 3c diabetes are controlling the blood sugar levels.
Researchers looked into those patients who were diagnosed with diabetes after the damage to pancreas due to events such as hemochromatosis, cystic fibrosis, pancreatic cancer and tumors, pancreatitis and pancreatic surgery, which may increase the risk of type 3c diabetes or pancreatogenic diabetes (T3cD). The study has found.
* Only three percent of the patients with type 3c diabetes were being diagnosed properly as type 3c diabetes.
* Type 3c diabetes was more prevalent than type 1 diabetes (T1D). The new patients of type 1 diabetes (T1D) were one percent and the new patients of type 3c diabetes were 1.6 percent.
* Management of blood sugar levels is twice more likely to be poor among patients of type 3c diabetes when compared with patients of type 2 diabetes (T2D).
* The criteria for the insulin requirement in patients of type 3c diabetes are the pancreas disease, damage or injury. The requirement of Insulin is five to ten times more in patients of type 3c diabetes when compared with patients of type 2 diabetes (T2D).
The study is increasing the concerns that the type 3c diabetes is more common and this type of diabetes is not being diagnosed properly. Misdiagnosis of type 3c diabetes is a waste of time, money and a risk of high blood sugar (glucose) levels.
Drugs such as gliclazide and the treatment of type 2 diabetes (T2D) are not effective in the treatment of type 3c diabetes. This small study shows the benefits for patients of type 3c diabetes with an insulin injection and digestive enzymes (in a tablet, liquid or pill form) along with the food.
Some tips for the prevention of type 3c diabetes or pancreatogenic diabetes (T3cD) are.
Pancreatitis: Pancreas secretes glucagon and insulin hormone and releases them into the bloodstream to control the blood sugar levels. The pancreas also produces digestive enzymes and releases them into the small intestine for the digestion of the food.
In some people, these digestive enzymes were activated before being released into the small intestine. These enzymes attack the cells of the pancreas causing inflammation. This inflammation leads to pancreatitis. The symptoms of pancreatitis are.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.